A5101898006- Lung Cancer Diagnosis and Treatment
- Cancer Cells and Metastasis
- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Cancer, Hypoxia, and Metabolism
- Salivary Gland Tumors Diagnosis and Treatment
- Tracheal and airway disorders
- Pleural and Pulmonary Diseases
- Cancer-related gene regulation
- RNA modifications and cancer
- Tuberculosis Research and Epidemiology
- Diagnosis and treatment of tuberculosis
- Medical Imaging and Pathology Studies
- Infectious Diseases and Tuberculosis
- Epigenetics and DNA Methylation
- Peptidase Inhibition and Analysis
- Single-cell and spatial transcriptomics
- Immunotherapy and Immune Responses
- Cardiac tumors and thrombi
- Oral health in cancer treatment
- Fibroblast Growth Factor Research
- Head and Neck Anomalies
- Protease and Inhibitor Mechanisms
Beijing Chest Hospital
2015-2024
Capital Medical University
2015-2024
PURPOSE ADJUVANT-CTONG1104 (ClinicalTrials.gov identifier: NCT01405079 ), a randomized phase III trial, showed that adjuvant gefitinib treatment significantly improved disease-free survival (DFS) versus vinorelbine plus cisplatin (VP) in patients with epidermal growth factor receptor ( EGFR) mutation-positive resected stage II-IIIA (N1-N2) non–small-cell lung cancer (NSCLC). Here, we report the final overall (OS) results. METHODS From September 2011 to April 2014, 222 from 27 sites were...
Abstract The ADJUVANT study reported the comparative superiority of adjuvant gefitinib over chemotherapy in disease-free survival resected EGFR -mutant stage II–IIIA non-small cell lung cancer (NSCLC). However, not all patients experienced favorable clinical outcomes with tyrosine kinase inhibitors (TKI), raising necessity for further biomarker assessment. In this work, by comprehensive genomic profiling 171 tumor tissues from trial, five predictive biomarkers are identified ( TP53 exon4/5...
Abstract In vitro models coupled with multimodal approaches are needed to dissect the dynamic response of local tumor immune microenvironment (TIME) immunotherapy. Here patient‐derived primary lung cancer organoids (pLCOs) generated by isolating cell clusters, including infiltrated cells. A function‐associated single‐cell RNA sequencing (FascRNA‐seq) platform allowing both phenotypic evaluation and scRNA‐seq at single‐organoid level is developed TIME individual pLCOs. The analysis 171 pLCOs...
Both video-assisted thoracic surgery (VATS) and thoracotomy are used for sleeve lobectomy patients with non-small cell lung cancer (NSCLC). This retrospective study aimed to assess the safety efficacy of VATS NSCLC patients. Between May 2009 2013, 51 lobectomies (10 by 41 thoracotomy) were performed NSCLC. Operative characteristics postoperative course compared between two groups. Patient demographics similar Thoracotomy had larger tumors (p = 0.02). a longer operating time < 0.001) but...
The purpose of this study was to assess the postoperative complications after lung resection for non-small cell cancer (NSCLC) in elderly patients and identify possible associated risk factors.All aged 70 years or older who underwent pulmonary NSCLC by either an open approach a thoracoscopic between January 2003 December 2013 at our institution were reviewed. Postoperative events divided into minor major complications. Risk factors assessed univariate multivariate logistic regression...
Abstract Purpose Neoadjuvant PD-1 blockade combined with chemotherapy is a promising treatment for resectable non-small cell lung cancer (NSCLC), yet the immunological mechanisms contributing to tumor regression and biomarkers corresponding different pathological responses remain unclear. Methods Using dynamic paired blood samples from NSCLC patients receiving neoadjuvant chemoimmunotherapy, we analyzed frequencies of CD8 + T-cell Treg subsets their changes during through flow cytometry....
We tested the hypothesis that circulating tumor cells (CTCs) in preoperative peripheral blood (PPB) and intraoperative pulmonary venous (IPVB) could predict poor long-term survival resected non-small cell lung cancer (NSCLC) patients. CTCs were separated from using magnetic beads coated with antibodies against epithelial-cell adhesion molecule (EpCAM) via magnetic-activated sorting (MACS). quantified fluorescence-labeled pan-cytokeratin through flow cytometry. PPB IPVB 23 consecutive stage...
Background It has been reported that there are more circulating tumor cells (CTCs) in the pulmonary vein (PV) than peripheral blood; however, it is unclear whether CTC count changes PV after resection of a lung lobe. Methods Thirty‐three cancer patients were recruited for study, including 17 who underwent lobectomy via video‐assisted thoracoscopic surgery and 16 open thoracotomy. Sixty‐six blood specimens sampled from before was interrupted lobectomy. The CTCs quantified using...
Lung cancer is the most commonly diagnosed among men and it third ranked in women. There are two major types of lung cancer, namely, small cell (SCLC), which accounts for ~20% cases, non-small (NSCLC), common. Chemotherapy chemoradiotherapy have been used as first-line therapies but suffer from lack efficacy also several toxic adverse effects. Immunotherapeutic approaches including tumor antigen vaccination, monoclonal antibodies targeting checkpoint pathways activated immune cells being...
Abstract Background The outcomes of video-assisted thoracic bronchial sleeve lobectomy (VABSL), a minimally invasive thoracoscopic (VATS) lobectomy, are mostly unknown in Chinese patients. Objectives To investigate operative and postoperative VABSL cases series patients with lung cancer. Methods Retrospective study 9 (male:female 8:1; mean age 59.4 ± 17.6 years, ranging 21–79 years) diagnosed cancer single lobe, treated between March 2009 November 2011, followed up for at least 2 months...
8500 Background: Cisplatin-based adjuvant chemotherapy is standard of care for patients (pts) with stage II-IIIA non-small cell lung cancer (NSCLC). Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors have shown no benefits in the setting pts unselected resected NSCLC BR19 and RADIANT trials. ADJUVANT (NCT01405079) first randomized trial to compare gefitinib (G) vinorelbine+cisplatin (VP) completely pathological (N1-N2) EGFR-activating mutation. Methods: Completely mutation...
The aim of the present study was to develop a procedure for isolation circulating tumor cells (CTCs), and evaluate its application in detection epidermal growth factor receptor (EGFR) mutations, potential heterogeneity patients with non-small-cell lung cancer (NSCLC). Peripheral blood samples were collected from 91 cancer, 10 benign disease healthy volunteers. CTCs enriched by positive immunomagnetic separation, detected immunocytochemistry, processed single-cell capture. Pure CTC DNA...
Abstract Our main objective is probing the effect of methylation CLEC14A on its expression and lung adenocarcinoma (LUAD) progression. Microarray analysis was utilized to screen out differentially downregulated genes with hypermethylation in LUAD tissues. The level measured by western blot qRT‐PCR. Methylation‐specific‐PCR performed evaluate status . 3‐(4,5‐Dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromid (MTT) assay used check relation between cell proliferation. Cell cycle, apoptosis,...
The hMLH1 gene plays an essential role in DNA repair. Methylation of the is common many types cancer and can lead to loss expression. However, association clinicopathological significance between promoter hypermethylation non-small-cell lung (NSCLC) elusive. Here, we investigated correlation NSCLC using 13 studies by comprising 1,056 patients via a meta-analysis. We observed that 1) protein expression was significantly associated with its hypermethylation, 2) inactivation through contributed...
Background: Neoadjuvant chemoimmunotherapy (NACI) is promising for resectable nonsmall cell lung cancer (NSCLC), but predictive biomarkers are still lacking. The authors aimed to develop a model based on pretreatment parameters predict major pathological response (MPR) such an approach. Methods: enrolled operable NSCLC treated with NACI between March 2020 and May 2023 then collected baseline clinical-pathology data routine laboratory examinations before treatment. efficacy safety of this...
Personalized medicine has become essential in the treatment of lung cancer. However, cancer-related gene expression profiles non-small cell cancer (NSCLC) patients have not been elucidated. In this study, correlation between and clinicopathological characteristics was investigated NSCLC patients. A total 95 were enrolled study. The mRNA levels 14 genes assessed by multiplex branched DNA liquidchip (MBL) technology data on 9 collected simultaneously. investigated. Out parameters, 6 associated...
Background Personalized medicine becomes essential in lung cancer treatment, however lung-cancer-related gene expression profiles Chinese patients remain unknown. In this study, the correlation of and clinical characteristics non-small-cell (NSCLC) was investigated. Methods Seventy-six with NSCLC were enrolled study to investigate mRNA excision repair cross complement group 1 ( ERCC1 ), thymidylate synthetase TYMS ribonucleotide reductase RRM1 class III β-tubulin TUBB3 epidermal growth...
The butyrophilin (BTN) family has many members with diverse functions related to immunomodulation, initiation and progression of tumors. BTN3A3 belongs the BTN family, exploring its expression correlation prognosis non-small cell lung cancer (NSCLC) patients great clinical significance.Clinical specimens were used detect expression. Small interfering RNA (siRNA) was knock down analyze proliferative, migratory invading ability transfected NSCLC cells. Multiplex immunofluorescence staining...
IL-8 (interleukin-8) has been identified as a chemotactic factor, but recent found that and matrix metalloproteinase-9 (MMP-9) are important cytokines which closely related to the growth metastasis of tumor. The aim this study is explore relationship between IL-8, MMP-9 expressions clinical pathological features non-small cell lung cancer (NSCLC) patients evaluate diagnostic potential tumor markers.The serum levels were detected by enzyme-linked immunosorbentassay (ELISA) in 141 NSCLC...
Background: To investigate the expression levels of miRNA-29a (miR-29a), tumor necrosis factor-α (TNF-α) and vascular endothelial growth factor (VEGF) in peripheral blood pulmonary tuberculosis patients their correlation with clinical pathological features. Methods: A prospective analysis was performed on 192 (pulmonary group) 186 healthy (control who were admitted to Beijing Chest Hospital, Capital Medical University, Beijing, China from Jun 2015 2019. Real-time quantitative PCR used detect...
Preliminary researches conformed that neoadjuvant immunotherapy combined with chemotherapy had a significant short-term effect in resectable non-small cell lung cancer (NSCLC), but there were few clinical trials about chemoimmunotherapy China. We aimed to assess retrospectively the antitumour activity and safety of for stage Ib-IIIb NSCLC.Twenty patients who been diagnosed as NSCLC received treatment between November 2019 December 2020, Beijing Chest Hospital, Capital Medical University...